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Introduction
The formation of new blood vessels from preexisting vasculature, a process called angiogenesis, is essential for tumor growth [1] . Tumor endothelial marker 1 (TEM1) was first identified with a monoclonal antibody as a protein specifically expressed on tumor endothelial cells and was called endosialin by Rettig et al. [2] . Using 'serial analysis of gene expression' (SAGE) technology, TEM1 was again identified by St. Croix et al. as a tumor endothelial cell surface protein predominantly expressed on newly forming blood vessels [3, 4] . However, Opavsky et al. showed that the expression of this protein is more widespread [5] . An association with tumor development has been suggested again recently by the finding that TEM1 expression is elevated in breast cancer tissue and human brain tumors [6, 7] . TEM1 is a 165 kDa glycoprotein classified as a C-type lectin-like membrane receptor and is conserved in humans and mice. Its extracellular part consists of five globular domains (N-terminal C-type lectin domain, sushi-like domain, and three epidermal growth factor (EGF)-like repeats) and a mucin-like region. The core protein is heavily sialylated and displays similarity to thrombomodulin [8] . The normal function of human TEM1/endosialin is still unknown. Due to its increased expression on endothelial cells, its potential as a target molecule for tumor diagnosis and therapy has been proposed. Since TEM1 is located on the surface of tumor endothelial cells, it represents an easily accessible target in solid tumor tissue for antibody-or antibody conjugatemediated therapeutic intervention. Therapeutic targeting of the tumor vasculature, rather than the tumor cells themselves, has several advantages; firstly, endothelial cells are highly accessible for circulating drugs or drug carriers, secondly, endothelial cells are genetically stable and therefore less likely developing resistance towards cytotoxic drugs. Phage display and recombinant techniques have been employed to isolate single chain antibody fragments (scFvs) specific for a broad variety of antigens [9, 10] . ScFvs have also been successfully fused to a range of molecules in order to introduce different functionalities and secondary activity domains. Radioisotopes for cancer imaging, enzymes for prodrug therapy, toxins for targeted cell killing, viruses for gene therapy, liposomes for improved systemic delivery and biosensors for real-time detection of target molecules in live cells are among the most common applications of scFvs [11] [12] [13] [14] [15] [16] .
Liposomes are widely used as delivery systems to target specific tissues using a broad spectrum of agents including chemotherapeutics, imaging agents, antigens, lipids and DNA. Targeting of liposomes to specific sites of drug action is achieved by attachment of antibodies or antibody fragments to their surface. The resulting immunoliposomes show specific binding in vitro and in vivo and increased tumor to normal tissue distribution ratios [17, 18] .
We generated a scFv, scFv-CM6, with selectivity for the extracellular domains of the TEM1 protein using phage display technology. Its binding specificity was tested on purified protein in ELISA and Western blot analysis and on cells expressing TEM1 by fluorescence microscopy and flow cytometry. Specific binding of anti-TEM1-modified-scFv-liposomes (scFv-CM6-C-immunoliposomes) was demonstrated on the TEM1-expressing human neuroblastoma tumor cell line IMR-32 [2] . Anti-tumor activity of scFv-CM6-C-immunoliposomes was evaluated by loading with
, an amphiphilic cytotoxic compound which belongs to a new class of heterodinucleoside dimers that combine a lipophilic ara-C derivative (NOAC) [19] cytidine (ETC) [20] , which inhibits both RNA and DNA synthesis.
Materials and methods

Chemicals
The pGEX-2TK/GST-TEM1 vector was a kind gift of Dr. 0 -dioctadecyloxacarbocyanine perchlorate (DiO) from Molecular Probes (Leiden, The Netherlands). Sulfosuccinimidyl N-(carboxycyclohexylmethyl) maleimide (sulfo-SMCC) was from Pierce (Lausanne, Switzerland).
0 -C-ethinylcytidine (NOAC-ETC) was synthesized as described for similar dimers [19] . All buffer salts and other chemicals were of analytical grade and were obtained from Fluka or Sigma (Buchs, Switzerland).
Cell lines
Human embryonic kidney cells (HEK) 293T were maintained in DMEM. The human neuroblastoma cell line IMR-32 and the human colon carcinoma cell line HT-29 were a kind gift from Dr. I. Novak (Paul Scherrer Institut, Switzerland) and were maintained in RPMI 1640 medium supplemented with 1.5 mM sodium pyruvate and MEM non-essential amino acids. Each medium was completed with 10% fetal bovine serum (FBS), 1% L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin and 50 U/ml nystatin. The cells were cultured at 37 8C in an atmosphere of 5% CO 2 .
Generation of DNA constructs
The bicistronic plasmid pIRES (BD Biosciences Clontech, Germany) was modified to encode the signal sequence of the human vascular endothelial growth factor receptor 2 (VEGFR-2) followed by the extracellular TEM1 sequence and the transmembrane domain of VEGFR-2, giving rise to the vector pIRES/VE2-ss-TEM1-TM. The part of TEM1 was amplified from pGEX-2TK/GST-TEM1 by PCR using the forward 5 0 -GGAGACCCGGGCC-GACCCCTGGGCTGCTGAG-3 0 and reverse 5 0 -GCCGTGCCTACTAGAATAATGATCCAGCC A CCGTTGAAGGC-3 0 primers (Microsynth AG, Switzerland). The insertion of the PCR fragment into pIRES/VE2-ss-TM was accomplished using a PCR subcloning technique [21] . The pPICZaA_scFv-CM6-C plasmid for the expression of the functionalized scFv was constructed as described by Marty et al. [15] .
Production and purification of GST-TEM1
E. coli XL10 gold cells transformed with pGEX-2TK/GST-TEM1 or pGEX-2TK (Amersham Pharmacia Biotech, Sweden) plasmid were grown in LB medium containing ampicillin (100 mg/ml) until they had reached the mid-log phase where they were induced with isopropylthiogalactoside (IPTG, 0.2 mM). Cells were harvested by centrifugation after 4 h expression at 28 8C. Cell pellets were resuspended in lysis buffer (50 mM Tris-HCl, 5 mM EDTA, 10% glycerol, pH 7.4) in the presence of 1% Triton X-100, 1 mM phenylmethylsulfonylfluoride (PMSF), and 150 mg/ml lysozyme and the suspension was sonicated for 5 min. The soluble protein extract was isolated by centrifugation (10 000 g, 15 min, 4 8C) and purified by Glutathione-Sepharose column chromatography (Amersham Pharmacia Biotech, Sweden). The pure protein was eluted with freshly prepared 10 mM reduced glutathione in PBS (0.137 M NaCl, 2.68 mM KCl, 8.09 mM Na 2 HPO 4 , 1.76 mM KH 2 PO 4 ). Expression and isolation of the target protein was monitored by SDS-PAGE and the identity was confirmed by Western blotting using a rabbit anti-GST antibody.
Selection of specific scFv antibodies by biopanning
The construction of the library and the phage preparation was performed according to the method described by Pini et al. [9] . ScFv selection was carried out using GST-TEM1 as template as described by Rubio et al. [22] with the following minor change: for a first round of negative selection, the phage library was incubated at room temperature (RT) in GSTcoated tubes.
2.6. Expression and purification of scFvs in E. coli and P. pastoris and purification Production of the scFvs in E. coli HB2152 was carried out as described by Rubio et al. [22] . Production of scFvs in P. pastoris X-33 was carried out as described by Marty et al. [15] . ScFvs were purified on a Protein A column (Amersham Pharmacia Biotech, Sweden) according to the manufacturer. The protein was eluted with 100 mM glycine, pH 2.5 using an Aekta prime instrument column (Amersham Pharmacia Biotech, Sweden). Expression and isolation of the target protein was monitored by SDS-PAGE and the identity was confirmed by Western blotting using a mouse anti-flag M2 antibody.
Enzyme-linked immunosorbent assay (ELISA)
ELISA microtiter plates (Nunc GmbH, Wiesbaden, Germany) were coated overnight at 4 8C with 10 mg/ml GST-TEM1, GST or BSA, respectively. After coating the plates were washed five times with PBS and blocked for 2 h at RT with 2% MPBS (2% milk in PBS). A concentration range of 0.01-1000 nM purified scFvs prepared in 2% MPBS were incubated in the wells for 1 h at RT. Binding of scFvs was detected after 1 h incubation with mouse anti-flag M2 antibody and HRP-conjugated goat anti-mouse IgG prepared in 2% MPBS at RT. The color reaction was initiated by the addition of BM Blue POD substrate as described by the manufacturer and stopped with 1 M H 2 SO 4 after 15 min. The absorbance was read at 410 nm using a Dynatech microplate reader.
Binding of scFvs to immobilized GST-TEM1
Immobilization on PVDF membrane
The GST-TEM1 protein samples were analyzed on SDS-PAGE under reducing conditions and transferred onto a polyvinylidene (PVDF) membrane (Immobilon-P, Millipore, Switzerland). After blocking with MTBST (10 mM Tris-HCl, pH 8, 150 mM NaCl, 0.05% Tween supplemented with 2% milk) the membrane was incubated with scFvs (2 mg/ml) in MTBST for 1 h at RT. The detection on the membrane was completed by reaction with mouse anti-flag M2 and goat AP-conjugated anti-mouse antibodies, both in TBST, followed by color development with 36.6 mM 5-bromo-4-chloroindolylphosphate and 97.6 mM nitroblue-tetrazolium in DMF. Similarly, GST proteins were detected using a rabbit anti-GST IgG as primary and goat AP-conjugated anti-rabbit IgG as secondary antibody.
Immobilization on Glutathione beads
Glutathione-Sepharose beads were incubated with 1 mg/ml of GST or GST-TEM1, respectively, for 2 h at 4 8C according to the manufacturer's protocol. The beads were washed twice with PBS and incubated with scFv (20 mg/ml) for another 2 h at 4 8C. After washing twice with 0.5 M LiCl and 0.1 M Tris-HCl, pH 8, the beads were resuspended in SDS-PAGE loading buffer and boiled for 5 min at 95 8C. SDS-PAGE was performed and the proteins were transferred to an Immobilon-P transfer membrane and detected as described above.
Immunofluorescence
HEK 293T cells were transiently transfected with pIRES/VE2-ss-TEM1-TM using the calcium phosphate method. The cells were washed 24 h after transfection and incubated with purified scFvs (10 mg/ml) for 30 min, followed by incubation with mouse anti-flag M2 antibody and TRITC-labeled goat anti-mouse IgG. Finally, the cells were fixed in 3.7% formaldehyde, embedded in gelvatol, pH 7.5 and were examined with a Zeiss Axiophot epifluorescence microscope.
Liposome preparation
Small unilamellar liposomes (SUV) in phosphate buffer (PB, 67 mM, pH 7.4) with the composition of HSPC:Cholesterol:DPPE:DiO at a molar ratio of 1:0.2:0.07:0.004 and a mean diameter of 100 nm were prepared with a Lipexe extruder (Lipex Biomembranes Inc., Vancouver, Canada) as described by Marty et al. [17] . For cytotoxicity studies NOAC-ETC (7.5 mol% referred to HSPC) was added to the lipid mixture. Coupling of scFvs to liposomes was performed as described previously [17] . 
Cytotoxicity determination
Determination of cell viability was carried out as described previously [23] . Briefly, IMR-32 and HT-29 cells (10 000 cells/well) were seeded in growth medium for 24 h and cultured at 37 8C and 5% CO 2 in 96 well plates. Where indicated liposome binding was blocked by preincubation of the cells with a 100 fold excess of free scFv for 30 min. Liposomes containing NOAC-ETC or free NOAC-ETC at concentrations of 40 mM diluted in DMEM medium 1:1 (v/v) were added to the cells. After 1 h incubation, the liposome containing medium was removed and replaced by growth medium for 24 h. Cell viability was determined with the WST-1 test using a Dynatech MR 4000 plate reader. All measurements were carried out in quadruplicates.
Results
Isolation, production and characterization of GST-TEM1, scFv-CM6 and scFv-CM6-C
The extracellular part of TEM1 (amino acids 1-271) fused to the carboxyterminus of GST was produced in E. coli with a yield of 2 mg/l, purified on Glutathione-Sepharose and analyzed by SDS-PAGE (Fig. 1, lane 2) and Western blotting (Fig. 1, lane 5) . The fusion protein had the expected molecular weight of 64 kDa.
ScFvs specific for TEM1 were isolated from the ETH-2 phage display library using GST-TEM1 fusion protein immobilized on immunotubes. GST-specific phages were removed first by panning with GST, followed by three rounds of selection with GST-TEM1. Eight distinct positive clones out of 90 tested were identified. One clone, scFv-CM6, showed excellent binding properties in ELISA and a high production rate in bacteria and was used for scaled up production. ScFv-CM6 was expressed in E. coli HB2151 and exported to the bacterial periplasma via a PelB leader peptide. The yield of purified protein was typically 1-2 mg per 1 l of culture.
ScFv-CM6 was also produced in P. pastoris using the expression vector pPICZaA. The sequence was supplemented with a cysteine linker at the carboxy-terminus as described previously [15] . This scFv, termed scFv-CM6-C, was secreted into the culture supernatant of transformed P. pastoris and its expression was analyzed by SDS-PAGE and Western blot. Production was 5-10 fold improved relative to bacterial expression with yields up to 10 mg/l. ScFvs produced in E. coli or P. pastoris were purified in one step on a Protein A column. Fig. 1 shows detection of scFv-CM6 by SDS-PAGE (lane 3) and Western blotting (lane 6).
Characterization of scFv-CM6 and scFv-CM6-C
Binding of scFv-CM6 and scFv-CM6-C to TEM1 was first demonstrated by ELISA. Purified recombinant GST and GST-TEM1, respectively, immobilized on 96 well plastic plates were incubated with increasing concentrations of scFvs (Fig. 2(A) ). The affinity of scFv-CM6-C was identical to that of scFv-CM6. Both scFvs did not bind to GST, BSA nor untreated plastic. The binding properties of purified scFv-CM6 and scFv-CM6-C were further characterized by Western blot analysis. GST and GST-TEM1 were transferred onto a PVDF membrane and incubated with scFvs. As shown in Fig. 2(B) , scFv-CM6 specifically bound to GST-TEM1 (lane 1) but not to GST (lane 2), while the non-specific scFv-A1 bound neither to GST-TEM1 (lane 3) nor to GST (lane 4). Similar results were obtained for scFv-CM6-C (data not shown). Moreover, specific binding of scFv-CM6 and scFv-CM6-C was confirmed on GST-TEM1 coupled to Glutathione-Sepharose. ScFv-CM6 recognized native GST-TEM1 protein as shown in Fig. 2(C) , lane 2, but not GST (lane 1) or empty beads (lane 3). No binding was observed with scFv-A1 in all assays. The cysteine-modified in P. pastoris produced antibodies scFv-CM6-C and scFv-A1-C gave the same results as their bacterial counterparts (data not shown).
Binding of scFv-CM6 and scFv-CM6-C to TEM1-expressing cells
To test whether our scFvs recognize TEM1 located on the surface of cells, HEK 293T cells were transiently transfected with a bicistronic vector leading to expression of TEM1 fused to the signal sequence and transmembrane part of VEGF receptor 2 and to co-expression of green fluorescent protein (GFP). Transfection efficiency was determined by the number of GFP positive cells (Fig. 3(A) and (C) ). TEM1 protein was detected on the cell membrane by scFv-CM6 (Fig. 3(B) ) while the control scFv-A1 showed no staining (Fig. 3(D) ). Specific TEM1 recognition by scFv-CM6 was further confirmed by flow cytometry. ScFv-CM6 recognized IMR-32 tumor cells endogenously expressing TEM1 (Fig. 4(A) ), whereas no binding was detected on HT-29 cells that lack TEM1 (Fig. 4(B) ). Similar results were obtained with scFv-CM6-C (data not shown).
Properties of scFv-CM6-C-immunoliposomes
ScFv-CM6-C was coupled to the surface of liposomes as described earlier [17] . Fluorescencelabeled scFv-CM6-C-immunoliposomes showed higher binding activity to TEM1-expressing IMR-32 cells than control liposomes as examined by flow cytometry (Fig. 4(C) ) and no specific binding was observed on TEM1-negative HT-29 cells (Fig. 4(D) ).
Cytotoxicity of scFvCM6-C-NOAC-ETCimmunoliposomes
Immunoliposomes and control liposomes containing NOAC-ETC were added to IMR-32 and HT-29 3) and GST (lanes 2, 4) were detected with scFv-CM6 (lanes 1, 2) or the non-specific scFv-A1 (lanes 3, 4) used as primary antibodies in Western blot analysis. (C) GST (lane 1), GST-TEM1 (lane 2) and untreated beads (lane 3) were incubated with scFv-CM6 for 30 min, washed and analyzed on Western blots using anti-flag M2 primary antibody. cells, respectively, for 1 h and cell survival was determined after 24 h. As shown in Fig. 5 , scFv-CM6-C-NOAC-ETC-immunoliposomes reduced cell viability of TEM1-expressing cells by 82% compared to control NOAC-ETC-liposomes. Less toxicity was observed when the TEM1-negative cell line HT-29 was treated with scFv-CM6-C-NOAC-ETC-immunoliposomes. To demonstrate the specificity of scFv-CM6-immunoliposomes, IMR-32 cells were first treated with soluble scFv-CM6-C followed by incubation with cytotoxic immunoliposomes. The toxicity of the immunoliposomes was almost completely blocked as shown in Fig. 5 (bar 4) while preincubation with a non-specific control antibody showed no blocking effects (Fig. 5, bar 5 ). This experiment shows that TEM1-specific immunoliposomes preferentially kill TEM1-expressing cells while leaving control cells unaffected. Immunoliposomes without NOAC-ETC were not toxic (data not shown) and serum had no influence on the effect of liposomes loaded with NOAC-ETC (data not shown). As expected, free NOAC-ETC showed similar toxicity towards both cell lines (Fig. 5, bars 6 and 12 ).
Discussion
Here we describe the isolation and characterization of a single chain recombinant antibody, scFv-CM6 that recognizes tumor endothelial marker 1. TEM1 is a membrane protein predominantly expressed on tumor endothelial cells and on some tumor cells and is therefore well suited for targeted tumor therapy [3, 4] . Other angiogenic markers such as endoglin, VEGFR-2, VEGF or the ED-B splice variant of fibronectin have been shown before to represent good targets for tumor vasculature-specific cancer therapy [24] [25] [26] [27] .
In the past years, phage display of peptides and proteins has become an important method and was successfully used in protein engineering, ligandreceptor interaction studies and for generating antibody fragments to target tissues in live organisms. Phage display libraries such as the ETH-2 library described by Pini et al. [9] are convenient tools to isolate antibody fragments specific for a plethora of antigens. Our scFv-CM6 was isolated by phage display using the extracellular part of human TEM1 fused to GST and was initially produced in E. coli. Since one of the factors limiting the application of scFv therapy is the low amount that can be produced by bacterial expression systems, we chose the yeast P. pastoris to increase the production yield of scFv proteins [15] . While recloning our scFv into the yeast expression vector, we also added new features that expand their use as targeting reagents. Three cysteine residues and a glycine linker were added at the carboxyterminus of the scFv-CM6 sequence in order to allow coupling the protein to drugs, toxins, radioisotopes or for the linkage to the surface of liposomes via a maleimide linker [17] . Bacterially and yeast produced scFvs showed the same binding properties on purified TEM1 protein (Fig. 2) .
We next investigated whether scFv-CM6 is able to recognize TEM1 expressed on the surface of living cells. Whereas scFv-CM6 specifically bound to TEM1 located on the membrane of transiently transfected HEK 293T cells and on tumor cells such as IMR-32 that endogenously express TEM1, control scFv showed no binding (Figs. 3 and 4) . This supports the concept that TEM1-specific antibodies are excellent tools for cell-specific targeting.
Immunoliposomes have been successfully used in the past as carriers for therapeutic drugs, toxins, radioisotopes or fluorescent markers for targeted inhibition of tumor growth [28, 29] . In our previous study we demonstrated tumor-specific targeting of immunoliposomes modified with a scFv recognizing the ED-B isoform of fibronectin, an extracellular matrix protein highly expressed in well vascularized F9 tumors that can be grown in nude and Sv129 mice [17] . In this study we coupled the cysteine-modified TEM1 antibody (scFv-CM6-C) with an efficiency of approximately 30% to liposomes taking advantage of a coupling method that preserves protein activity. This method is based on the conjugation of thiolated proteins to carriers modified with cysteine-reactive maleimide groups. Target cell-specific immunoliposomes offer the possibility to use nucleoside duplex drugs in combination with water soluble cytotoxic compounds such as e.g. doxorubicin or mitoxantrone. Alternatively, anti-angiogenic molecules such as fumagallin derivatives (TNP-470) can be concomitantly incorporated into liposomes. Our scFv-CM6-Cimmunoliposomes were loaded with NOAC-ETC, a cytotoxic amphiphilic nucleoside duplex molecule recently developed by our laboratories. The chemical combination of NOAC [19] and ETC [20] gives rise to a heterodinucleoside drug with high cytotoxicity against solid tumors that can be efficiently incorporated into the lipid membrane of liposomes. Therapeutic targeting and cytotoxicity of our scFv-CM6-C-NOAC-ETC-immunoliposomes were successfully tested on TEM1-expressing cells as shown in Fig. 5 . Specificity of immunoliposome targeting was further demonstrated by blocking TEM1 with soluble free scFv which resulted in almost complete inhibition of liposomal cytotoxicity.
Whether TEM1 is internalized or not is at present unclear and the mechanism underlying drug uptake into cells must be further investigated. The function of TEM1 may be to concentrate liposomes on the surface of target cells and thereby to promote their fusion with the cell membrane. This will result in the release of the drug into target cells.
Since the tumor vasculature is easily accessible for drug carriers circulating in the blood, the use of TEM1-targeted reagents represents a promising strategy for cancer therapy. Such a therapy is aimed predominantly at the destruction of the genetically stable tumor vasculature which shows a low mutation rate and is therefore expected to lead to reduced therapy resistance. TEM1-specific targeting with immunoliposomes is a novel approach for efficient anti-angiogenic therapy. As TEM1 is also expressed on tumor cells, our scFv-CM6 represents a useful reagent for tumor diagnosis. In addition, the scFvs described here are promising tools to investigate the role of TEM1 in the development of new blood vessels, for instance in the vicinity of tumor lesions. 
